-
Something wrong with this record ?
Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID)
M. Aziz, M. Simonato, JG. Webb, M. Abdel-Wahab, D. McElhinney, A. Duncan, D. Tchetche, M. Barbanti, AS. Petronio, F. Maisano, VG. Ribeiro, DF. Gaia, R. Rana, V. Kocka, M. Mathur, H. Wijeysundera, F. Hellig, H. Nissen, R. Bekeredjian, C. Rihal,...
Language English Country United States
Document type Comparative Study, Journal Article, Multicenter Study, Observational Study
PubMed
30079597
DOI
10.1002/ccd.27714
Knihovny.cz E-resources
- MeSH
- Aortic Valve physiopathology surgery MeSH
- Bioprosthesis * MeSH
- Time Factors MeSH
- Heart Valve Prosthesis Implantation adverse effects instrumentation mortality MeSH
- Risk Assessment MeSH
- Humans MeSH
- Decision Support Techniques * MeSH
- Predictive Value of Tests MeSH
- Prosthesis Design MeSH
- Registries MeSH
- Risk Factors MeSH
- Prosthesis Failure * MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Heart Valve Prosthesis * MeSH
- Transcatheter Aortic Valve Replacement adverse effects instrumentation mortality MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Comparative Study MeSH
BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS). OBJECTIVE: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all-cause mortality after transcatheter aortic valve-in-valve (ViV) implantations, which was not assessed before. METHODS: Using the Valve-in-Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30-day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination. RESULTS: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30-day mortality with ratios of 0.176 (95% CI 0.138-0.214), 0.342 (95% CI 0.264-0.419), and 0.536 (95% CI 0.421-0.651), respectively. 30-day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698. CONCLUSIONS: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.
3rd Faculty of Medicine Charles University Prague Czech Republic
Azienda Ospedaliero Universitaria Pisana Pisa Italy
Centro Hospitalar Vila Nova de Gaia Vila Nova de Gaia Portugal
Clinique Pasteur Toulouse France
Escola Paulista de Medicina UNIFESP São Paulo Brazil
Ferrarotto Hospital Catania Italy
Mayo Clinic Rochester Minnesota
Odense University Hospital Odense Denmark
Royal Brompton Hospital London United Kingdom
Segeberger Kliniken Bad Segeberg Germany
St Paul's Hospital Vancouver Canada
St Paul's Hospital Vancouver Canada Escola Paulista de Medicina UNIFESP São Paulo Brazil
St Paul's Hospital Vancouver Canada University of Washington Seattle Washington
Stanford University School of Medicine Stanford California
Sunninghill Hospital Johannesburg Republic of South Africa
Sunnybrook Hospital Toronto Canada
The Alfred Hospital Melbourne Australia
University Hospital Heidelberg Heidelberg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045322
- 003
- CZ-PrNML
- 005
- 20200113104954.0
- 007
- ta
- 008
- 200109s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ccd.27714 $2 doi
- 035 __
- $a (PubMed)30079597
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Aziz, Mina $u St. Paul's Hospital, Vancouver, Canada.
- 245 10
- $a Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID) / $c M. Aziz, M. Simonato, JG. Webb, M. Abdel-Wahab, D. McElhinney, A. Duncan, D. Tchetche, M. Barbanti, AS. Petronio, F. Maisano, VG. Ribeiro, DF. Gaia, R. Rana, V. Kocka, M. Mathur, H. Wijeysundera, F. Hellig, H. Nissen, R. Bekeredjian, C. Rihal, SJ. Duffy, D. Dvir,
- 520 9_
- $a BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS). OBJECTIVE: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all-cause mortality after transcatheter aortic valve-in-valve (ViV) implantations, which was not assessed before. METHODS: Using the Valve-in-Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30-day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination. RESULTS: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30-day mortality with ratios of 0.176 (95% CI 0.138-0.214), 0.342 (95% CI 0.264-0.419), and 0.536 (95% CI 0.421-0.651), respectively. 30-day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698. CONCLUSIONS: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a aortální chlopeň $x patofyziologie $x chirurgie $7 D001021
- 650 12
- $a bioprotézy $7 D001705
- 650 12
- $a metody pro podporu rozhodování $7 D003661
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a srdeční chlopně umělé $7 D006350
- 650 _2
- $a chirurgická náhrada chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D019918
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a protézy - design $7 D011474
- 650 12
- $a selhání protézy $7 D011475
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a transkatetrální implantace aortální chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D065467
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Simonato, Matheus $u St. Paul's Hospital, Vancouver, Canada. Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil.
- 700 1_
- $a Webb, John G $u St. Paul's Hospital, Vancouver, Canada.
- 700 1_
- $a Abdel-Wahab, Mohamed $u Segeberger Kliniken, Bad Segeberg, Germany.
- 700 1_
- $a McElhinney, Doff $u Stanford University School of Medicine, Stanford, California.
- 700 1_
- $a Duncan, Alison $u Royal Brompton Hospital, London, United Kingdom.
- 700 1_
- $a Tchetche, Didier $u Clinique Pasteur, Toulouse, France.
- 700 1_
- $a Barbanti, Marco $u Ferrarotto Hospital, Catania, Italy.
- 700 1_
- $a Petronio, Anna Sonia $u Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
- 700 1_
- $a Maisano, Francesco $u University Hospital Zürich, Zürich, Switzerland.
- 700 1_
- $a Ribeiro, Vasco Gama $u Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal.
- 700 1_
- $a Gaia, Diego Felipe $u Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil.
- 700 1_
- $a Rana, Ruhina $u St. Paul's Hospital, Vancouver, Canada.
- 700 1_
- $a Kocka, Viktor $u Third Faculty of Medicine - Charles University, Prague, Czech Republic.
- 700 1_
- $a Mathur, Moses $u University of Washington, Seattle, Washington.
- 700 1_
- $a Wijeysundera, Harindra $u Sunnybrook Hospital, Toronto, Canada.
- 700 1_
- $a Hellig, Farrel $u Sunninghill Hospital, Johannesburg, Republic of South Africa.
- 700 1_
- $a Nissen, Henrik $u Odense University Hospital, Odense, Denmark.
- 700 1_
- $a Bekeredjian, Raffi $u University Hospital Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Rihal, Charanjit $u Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Duffy, Stephen J $u The Alfred Hospital, Melbourne, Australia.
- 700 1_
- $a Dvir, Danny $u St. Paul's Hospital, Vancouver, Canada. University of Washington, Seattle, Washington.
- 773 0_
- $w MED00005333 $t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions $x 1522-726X $g Roč. 92, č. 6 (2018), s. 1163-1170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30079597 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113105326 $b ABA008
- 999 __
- $a ok $b bmc $g 1483591 $s 1083995
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 92 $c 6 $d 1163-1170 $e 20180805 $i 1522-726X $m Catheterization and cardiovascular interventions $n Catheter Cardiovasc Interv $x MED00005333
- LZP __
- $a Pubmed-20200109